Since April, about 30 institutional investors attended a plant survey organized by HaoHai Biological Technology on April 20 and May 25 respectively, during which the visitors were impressed by the high-growth four-part product mix and high-tech production facilities of the company.
 

During the survey, the plant manager detailed how a dosage of safe sodium hyaluronate product is produced, using the production of orthopedic sodium hyaluronate as an example. She told the visitors that the production of each product requires not only state-of-the-art technology but also rigorous end-to-end quality control efforts. The high-grade, sterile clean room and imported all-automatic sterile vacuum bottling facility ensure satisfactory production of each product.
 

During the survey, Ms. Huang Ling from the investor relations team of the company introduced the company profile, product mix and latest R&D status to attending investors, with focus on how thecompany has been doing its business in recent years.

Moreover, Ms. Chen Yiyi, executive director of the company, addressed the concerns of visiting investors about the core competitiveness and R&D status of HaoHai Biological Technology, the competitive advantage of Matrifill branded hyaluronic acid and this year’s strategy of the company’s orthopedic product line.